Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)

This study evaluated various remission criteria in abatacept plus methotrexate (MTX)-treated patients with early rheumatoid arthritis (RA). We aimed to investigate the time to, and sustainability of, remission, and to evaluate the relationship between remission, function and structure. Post hoc analyses were performed from the 12-month, double-blind period of the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE) in patients with early RA (≤2 years) and poor prognostic factors, comparing abatacept... Mehr ...

Verfasser: Smolen, Josef S
Dokumenttyp: Artikel
Reihe/Periodikum: Arthritis research & therapy
Verlag/Hrsg.: London, BioMed Central
Sprache: Englisch
ISSN: 1478-6354
Weitere Identifikatoren: doi: 10.1186/s13075-015-0671-9
Permalink: https://search.fid-benelux.de/Record/olc-benelux-1961017865
URL: NULL
NULL
Datenquelle: Online Contents Benelux; Originalkatalog
Powered By: Verbundzentrale des GBV (VZG)
Link(s) : http://dx.doi.org/10.1186/s13075-015-0671-9
http://dx.doi.org/10.1186/s13075-015-0671-9